Early improvement with lithium in classic mania and its association with later response

Carregando...
Imagem de Miniatura
Citações na Scopus
21
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
LUCKENBAUGH, David A.
MARCA, Getulio
HENTER, Ioline D.
BUSNELLO, Joao V.
ZARATE JR., Carlos A.
Citação
JOURNAL OF AFFECTIVE DISORDERS, v.144, n.1-2, p.160-164, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objectives: Despite lithium's clinical efficacy in treating mania in bipolar disorder (BD), studies evaluating early improvement and subsequent treatment response are sparse. This study investigated whether early improvement (within one week) to lithium monotherapy predicted later response and remission in individuals with BD mania. Methods: BD-I patients (n=46) experiencing a manic episode received lithium monotherapy for four weeks (initial dose: 600 mg/d, adjusted to therapeutic levels); individuals experiencing a mixed episode, rapid cyclers, previous non-responders to lithium, and those with current drug abuse/dependence were excluded. Symptoms were rated using the Young Mania Rating Scale (YMRS) at baseline and at Days 7, 14, 21, and 28. Results: Thirty-three percent of the total sample responded to lithium within the first week of treatment, defined as a >= 50% decrease from baseline YMRS scores; 63% responded by study endpoint. In addition, 39% of the total sample showed early improvement (at least 20% decrease in YMRS scores) after one week of treatment. In this group, 79% responded to lithium by study endpoint. Among those showing less than 20% improvement at Week 1, only 23% responded to lithium by study endpoint. Limitations: History of episodes sequence was not assessed. Conclusions: Early improvement in response to lithium monotherapy in subjects with BD mania predicted later response and remission. Most patients who did not show early improvement in response to lithium during the first week of treatment showed no response after one month. The findings provide a valuable clinical tool for early identification of those patients most likely to benefit from lithium in clinical practice.
Palavras-chave
Lithium, Mania, Early response, Treatment, Mood stabilizer
Referências
  1. American Psychiatric Association, 2002, THE AMERICAN JOURNAL, V159, P1
  2. COHEN S, 1989, J NERV MENT DIS, V177, P638, DOI 10.1097/00005053-198910000-00007
  3. Coryell W, 2000, BIOL PSYCHIAT, V47, P1034, DOI 10.1016/S0006-3223(00)00242-0
  4. DILSAVER SC, 1993, J PSYCHIATR NEUROSCI, V18, P61
  5. First M., 1996, STRUCTURED CLINICAL
  6. Goldberg JF, 1999, J CLIN PSYCHIAT, V60, P733
  7. Goodnick P.J., 1996, PREDICTORS OF TREATM
  8. GROF E, 1987, PROG NEURO-PSYCHOPH, V11, P199, DOI 10.1016/0278-5846(87)90060-1
  9. Grof P, 2010, NEUROPSYCHOBIOLOGY, V62, P8, DOI 10.1159/000314305
  10. HIMMELHOCH JM, 1986, PSYCHOPHARMACOL BULL, V22, P613
  11. Houston JP, 2011, J PSYCHIATR RES, V45, P169, DOI 10.1016/j.jpsychires.2010.05.016
  12. Katz M M, 1996, Depress Anxiety, V4, P257, DOI 10.1002/(SICI)1520-6394(1996)4:6<257::AID-DA1>3.0.CO;2-9
  13. KELLER MB, 1986, JAMA-J AM MED ASSOC, V255, P3138, DOI 10.1001/jama.255.22.3138
  14. Kemp DE, 2011, J AFFECT DISORDERS, V130, P171, DOI 10.1016/j.jad.2010.10.026
  15. Kemp D.E., 2011, J CLIN PSYCHIAT
  16. Kessing LV, 2011, INT CLIN PSYCHOPHARM, V26, P323, DOI 10.1097/YIC.0b013e32834a5cd0
  17. Ketter TA, 2010, J PSYCHIATR RES, V44, P8, DOI 10.1016/j.jpsychires.2009.07.006
  18. KUKOPULOS A, 1980, PHARMAKOPSYCH NEURO, V13, P156
  19. Machado-Vieira R, 2008, J CLIN PSYCHIAT, V69, P1237
  20. Maj M, 2003, BIPOLAR DISORD, V5, P180, DOI 10.1034/j.1399-5618.2003.00002.x
  21. MCELROY SL, 1992, AM J PSYCHIAT, V149, P1633
  22. NAGAYAMA H, 1991, J AFFECT DISORDERS, V23, P213, DOI 10.1016/0165-0327(91)90102-X
  23. NIERENBERG AA, 1995, AM J PSYCHIAT, V152, P1500
  24. SECUNDA SK, 1985, J AFFECT DISORDERS, V8, P113, DOI 10.1016/0165-0327(85)90033-3
  25. Stassen HH, 1996, PHARMACOPSYCHIATRY, V29, P87, DOI 10.1055/s-2007-979551
  26. Stassen HH, 1999, PHARMACOPSYCHIATRY, V32, P56, DOI 10.1055/s-2007-979192
  27. Stassen H H, 1993, Eur Neuropsychopharmacol, V3, P127, DOI 10.1016/0924-977X(93)90264-M
  28. Suppes T, 2005, J CLIN PSYCHIAT, V66, P870
  29. Swann AC, 1997, ARCH GEN PSYCHIAT, V54, P37
  30. Szegedi A, 2009, J CLIN PSYCHIAT, V70, P344
  31. Tohen M, 2010, J CLIN PSYCHIAT, V71, P451, DOI 10.4088/JCP.08m04984gre
  32. Yatham LN, 2009, BIPOLAR DISORD, V11, P225, DOI 10.1111/j.1399-5618.2009.00672.x
  33. Young R.C., 1978, THE BRITISH JOURNAL, V133, P429